Skip to Main Content

Paper Details

Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia.
Blood
986
2017
Author NameAffiliation
Courtney D DiNardoThe University of Texas MD Anderson Cancer Center
Daniel A PollyeaUniversity of Colorado School of Medicine
Richard M StoneDana-Farber Cancer Institute
Daniel J DeAngeloDana-Farber Cancer Institute
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
Robert H CollinsUniversity of Texas Southwestern Medical Center
Ronan SwordsSylvester Comprehensive Cancer Center, University of Miami
Bruno C MedeirosStanford Comprehensive Cancer Center, Stanford University
Martin S TallmanMemorial Sloan Kettering Cancer Center
Martin S TallmanWeill Cornell Medical College
  • 1 - 10

Datasets

Release 1.2